Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis

David A. Bushinsky, Patrick Rossignol, David M. Spiegel, Wade W. Benton, Jinwei Yuan, Geoffrey A. Block, Christopher S. Wilcox, Rajiv Agarwal

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased mortality, and treatment options are limited. The effect of patiromer, a gastrointestinal K binder, on serum K was examined in HD patients. Methods: Six hyperkalemic HD patients (5 anuric) were admitted to clinical research units for 15 days (1 pretreatment week and 1 patiromer treatment week) and they received a controlled diet with identical meals on corresponding days of pretreatment and treatment weeks. Phosphate (P) binders were discontinued on admission. Patiromer, 12.6 g daily (divided 4.2 g TID with meals), was started on the Monday morning following the last pretreatment week blood sampling. Serum and 24-hour stool samples were collected daily. Results: Mean ± SE serum K decreased (maximum change per corresponding day, 0.6 ± 0.2 mEq/l, p = 0.009) and fecal K increased 58% on patiromer compared with the pretreatment week. During the pretreatment week, 69.0, 47.6, and 11.9% of patients' serum K values were ≥5.5, ≥6.0, and ≥6.5 mEq/l, respectively. This was reduced to 38.1% (p = 0.009), 11.9% (p < 0.001), and 2.4% (p = 0.2) on patiromer. Following P binder discontinuation, the long interdialytic interval mean ± SE serum P numerically increased from 5.8 ± 0.4 to 7.0 ± 0.5 mg/dl (p = 0.06). On patiromer, P decreased from 7.0 ± 0.5 to 6.2 ± 0.5 mg/dl (p = 0.04). While on patiromer, fecal P numerically increased by 112 ± 72 mg/day (17%; p = 0.1792; range -148 to 344 mg/day). No patient discontinued patiromer because of adverse events (AEs); none had serious AEs. Conclusions: In 6 hyperkalemic HD patients, patiromer decreased serum K and P levels and increased fecal K.

Original languageEnglish (US)
Pages (from-to)404-410
Number of pages7
JournalAmerican Journal of Nephrology
Volume44
Issue number5
DOIs
StatePublished - Nov 1 2016

Fingerprint

Renal Dialysis
Serum
Meals
patiromer
potassium phosphate
Hyperkalemia
Potassium
Therapeutics
Phosphates
Diet
Mortality
Research

Keywords

  • End-stage renal disease
  • Hemodialysis
  • Hyperkalemia
  • Patiromer
  • Phosphate
  • Potassium

ASJC Scopus subject areas

  • Nephrology

Cite this

Bushinsky, D. A., Rossignol, P., Spiegel, D. M., Benton, W. W., Yuan, J., Block, G. A., ... Agarwal, R. (2016). Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis. American Journal of Nephrology, 44(5), 404-410. https://doi.org/10.1159/000451067

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis. / Bushinsky, David A.; Rossignol, Patrick; Spiegel, David M.; Benton, Wade W.; Yuan, Jinwei; Block, Geoffrey A.; Wilcox, Christopher S.; Agarwal, Rajiv.

In: American Journal of Nephrology, Vol. 44, No. 5, 01.11.2016, p. 404-410.

Research output: Contribution to journalArticle

Bushinsky, DA, Rossignol, P, Spiegel, DM, Benton, WW, Yuan, J, Block, GA, Wilcox, CS & Agarwal, R 2016, 'Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis', American Journal of Nephrology, vol. 44, no. 5, pp. 404-410. https://doi.org/10.1159/000451067
Bushinsky DA, Rossignol P, Spiegel DM, Benton WW, Yuan J, Block GA et al. Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis. American Journal of Nephrology. 2016 Nov 1;44(5):404-410. https://doi.org/10.1159/000451067
Bushinsky, David A. ; Rossignol, Patrick ; Spiegel, David M. ; Benton, Wade W. ; Yuan, Jinwei ; Block, Geoffrey A. ; Wilcox, Christopher S. ; Agarwal, Rajiv. / Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis. In: American Journal of Nephrology. 2016 ; Vol. 44, No. 5. pp. 404-410.
@article{83a389db74c94a7dbc8bcaf57f05a3ee,
title = "Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis",
abstract = "Background: Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased mortality, and treatment options are limited. The effect of patiromer, a gastrointestinal K binder, on serum K was examined in HD patients. Methods: Six hyperkalemic HD patients (5 anuric) were admitted to clinical research units for 15 days (1 pretreatment week and 1 patiromer treatment week) and they received a controlled diet with identical meals on corresponding days of pretreatment and treatment weeks. Phosphate (P) binders were discontinued on admission. Patiromer, 12.6 g daily (divided 4.2 g TID with meals), was started on the Monday morning following the last pretreatment week blood sampling. Serum and 24-hour stool samples were collected daily. Results: Mean ± SE serum K decreased (maximum change per corresponding day, 0.6 ± 0.2 mEq/l, p = 0.009) and fecal K increased 58{\%} on patiromer compared with the pretreatment week. During the pretreatment week, 69.0, 47.6, and 11.9{\%} of patients' serum K values were ≥5.5, ≥6.0, and ≥6.5 mEq/l, respectively. This was reduced to 38.1{\%} (p = 0.009), 11.9{\%} (p < 0.001), and 2.4{\%} (p = 0.2) on patiromer. Following P binder discontinuation, the long interdialytic interval mean ± SE serum P numerically increased from 5.8 ± 0.4 to 7.0 ± 0.5 mg/dl (p = 0.06). On patiromer, P decreased from 7.0 ± 0.5 to 6.2 ± 0.5 mg/dl (p = 0.04). While on patiromer, fecal P numerically increased by 112 ± 72 mg/day (17{\%}; p = 0.1792; range -148 to 344 mg/day). No patient discontinued patiromer because of adverse events (AEs); none had serious AEs. Conclusions: In 6 hyperkalemic HD patients, patiromer decreased serum K and P levels and increased fecal K.",
keywords = "End-stage renal disease, Hemodialysis, Hyperkalemia, Patiromer, Phosphate, Potassium",
author = "Bushinsky, {David A.} and Patrick Rossignol and Spiegel, {David M.} and Benton, {Wade W.} and Jinwei Yuan and Block, {Geoffrey A.} and Wilcox, {Christopher S.} and Rajiv Agarwal",
year = "2016",
month = "11",
day = "1",
doi = "10.1159/000451067",
language = "English (US)",
volume = "44",
pages = "404--410",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis

AU - Bushinsky, David A.

AU - Rossignol, Patrick

AU - Spiegel, David M.

AU - Benton, Wade W.

AU - Yuan, Jinwei

AU - Block, Geoffrey A.

AU - Wilcox, Christopher S.

AU - Agarwal, Rajiv

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased mortality, and treatment options are limited. The effect of patiromer, a gastrointestinal K binder, on serum K was examined in HD patients. Methods: Six hyperkalemic HD patients (5 anuric) were admitted to clinical research units for 15 days (1 pretreatment week and 1 patiromer treatment week) and they received a controlled diet with identical meals on corresponding days of pretreatment and treatment weeks. Phosphate (P) binders were discontinued on admission. Patiromer, 12.6 g daily (divided 4.2 g TID with meals), was started on the Monday morning following the last pretreatment week blood sampling. Serum and 24-hour stool samples were collected daily. Results: Mean ± SE serum K decreased (maximum change per corresponding day, 0.6 ± 0.2 mEq/l, p = 0.009) and fecal K increased 58% on patiromer compared with the pretreatment week. During the pretreatment week, 69.0, 47.6, and 11.9% of patients' serum K values were ≥5.5, ≥6.0, and ≥6.5 mEq/l, respectively. This was reduced to 38.1% (p = 0.009), 11.9% (p < 0.001), and 2.4% (p = 0.2) on patiromer. Following P binder discontinuation, the long interdialytic interval mean ± SE serum P numerically increased from 5.8 ± 0.4 to 7.0 ± 0.5 mg/dl (p = 0.06). On patiromer, P decreased from 7.0 ± 0.5 to 6.2 ± 0.5 mg/dl (p = 0.04). While on patiromer, fecal P numerically increased by 112 ± 72 mg/day (17%; p = 0.1792; range -148 to 344 mg/day). No patient discontinued patiromer because of adverse events (AEs); none had serious AEs. Conclusions: In 6 hyperkalemic HD patients, patiromer decreased serum K and P levels and increased fecal K.

AB - Background: Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased mortality, and treatment options are limited. The effect of patiromer, a gastrointestinal K binder, on serum K was examined in HD patients. Methods: Six hyperkalemic HD patients (5 anuric) were admitted to clinical research units for 15 days (1 pretreatment week and 1 patiromer treatment week) and they received a controlled diet with identical meals on corresponding days of pretreatment and treatment weeks. Phosphate (P) binders were discontinued on admission. Patiromer, 12.6 g daily (divided 4.2 g TID with meals), was started on the Monday morning following the last pretreatment week blood sampling. Serum and 24-hour stool samples were collected daily. Results: Mean ± SE serum K decreased (maximum change per corresponding day, 0.6 ± 0.2 mEq/l, p = 0.009) and fecal K increased 58% on patiromer compared with the pretreatment week. During the pretreatment week, 69.0, 47.6, and 11.9% of patients' serum K values were ≥5.5, ≥6.0, and ≥6.5 mEq/l, respectively. This was reduced to 38.1% (p = 0.009), 11.9% (p < 0.001), and 2.4% (p = 0.2) on patiromer. Following P binder discontinuation, the long interdialytic interval mean ± SE serum P numerically increased from 5.8 ± 0.4 to 7.0 ± 0.5 mg/dl (p = 0.06). On patiromer, P decreased from 7.0 ± 0.5 to 6.2 ± 0.5 mg/dl (p = 0.04). While on patiromer, fecal P numerically increased by 112 ± 72 mg/day (17%; p = 0.1792; range -148 to 344 mg/day). No patient discontinued patiromer because of adverse events (AEs); none had serious AEs. Conclusions: In 6 hyperkalemic HD patients, patiromer decreased serum K and P levels and increased fecal K.

KW - End-stage renal disease

KW - Hemodialysis

KW - Hyperkalemia

KW - Patiromer

KW - Phosphate

KW - Potassium

UR - http://www.scopus.com/inward/record.url?scp=84992709206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992709206&partnerID=8YFLogxK

U2 - 10.1159/000451067

DO - 10.1159/000451067

M3 - Article

VL - 44

SP - 404

EP - 410

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 5

ER -